Welcome to our dedicated page for LOGICMARK news (Ticker: LGMKD), a resource for investors and traders seeking the latest updates and insights on LOGICMARK stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LOGICMARK's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LOGICMARK's position in the market.
LogicMark (OTC: LGMKD) reported third-quarter 2025 results for the period ended September 30, 2025. Revenue rose 8% year-over-year to $2.9 million. Gross margin remained stable at 66% for the three and nine months ended September 30, 2025. Gross profit was $1.9 million. Total operating expenses increased by $0.2 million (5%) to $3.7 million, driven by added sales hires. Net loss was $1.7 million; loss per diluted share was $2.21 after a reverse stock split in October 2025. Cash and investments totaled $11.7 million with no long-term debt. The company launched Medication Reminders and Activity Metrics on Freedom Alert Max and will host an investor webcast on November 12, 2025.
FAQ
What is the current stock price of LOGICMARK (LGMKD)?
